<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364491</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-TXA</org_study_id>
    <secondary_id>U10HD036801</secondary_id>
    <nct_id>NCT03364491</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean</brief_title>
  <acronym>TXA</acronym>
  <official_title>Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo-controlled trial of 11,000 women to assess whether tranexamic acid as
      prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstetrical hemorrhage is a common cause of maternal morbidity and mortality worldwide. The
      frequency and severity of hemorrhage is significantly higher after cesarean delivery than
      vaginal delivery. Recent evidence has emerged about the importance of the fibrinolytic
      pathway in the pathophysiology of hemorrhage in different clinical scenarios including
      trauma-associated bleeding, cardiovascular surgery, and obstetrical hemorrhage. Tranexamic
      acid (TXA) inhibits fibrinolysis and is used routinely to prevent hemorrhage in trauma cases
      and high risk surgeries. Randomized trials of TXA as a prophylaxis to prevent hemorrhage in
      cesarean delivery have been small and of mixed quality; however meta-analysis suggests that
      it is effective.

      This study is a randomized placebo-controlled trial of 11,000 women to assess whether
      tranexamic acid as prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a
      cesarean delivery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive either TXA (1 gram [10cc] mixed with 40 cc of normal saline) administered intravenously or a placebo control of 50 cc of normal saline administered intravenously</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patient nor the clinical staff will be aware of the treatment assignment. The TXA or placebo solutions will be prepared by the center research pharmacies.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal death or transfusion of packed red blood cells</measure>
    <time_frame>by hospital discharge or by 7 days postpartum, whichever is sooner</time_frame>
    <description>Maternal death or transfusion of 1 or more units of packed red blood cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>From skin incision to transfer from operating room, average of 1 hour</time_frame>
    <description>Estimated blood loss in milliliters, collected from anesthesia record and operative report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death or transfusion of packed red blood cells</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Maternal death or transfusion of 1 or more units of packed red blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of surgical or radiological interventions to control bleeding and related complications, or maternal death</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Interventions such as: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of maternal death, thromboembolic events (venous or arterial), ischemic stroke, myocardial infarction, new-onset seizure activity, or admission to the intensive care unit for more than 24 hours</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related acute lung injury (TRALI)</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Ratio of partial pressure of oxygen to inspired fraction of oxygen below 300 within 6 hours of receiving a blood product with bilateral pulmonary edema on chest x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of other blood products</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of 4 or more units of packed red blood cells</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Amount of packed red blood cells transfused, categorized as 0 to 3 units, or 4 or more units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Acute elevation of serum creatinine of â‰¥ 0.3 mg/dL during a period of 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events (venous or arterial), ischemic stroke, or myocardial infarction</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset seizure activity</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
    <description>Maternal seizure activity, confirmed by central review, whose onset is after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum infectious complications</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
    <description>Infectious complications such as: endometritis, surgical site infection, pelvic abscess</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to the intensive care unit for more than 24 hours</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
    <description>Any admission to the intensive care unit that lasts more than 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of uterotonics other than oxytocin</measure>
    <time_frame>within 48 hours postpartum</time_frame>
    <description>Any use of uterotonics such as prostaglandins or methergine, but excluding oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical or radiologic interventions to control bleeding and related complications</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Interventions such as: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>from 4 weeks before delivery to 48 hours postpartum</time_frame>
    <description>Change in hemoglobin from before cesarean to lowest post-operative measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TXA side effects</measure>
    <time_frame>within 24 hours postpartum</time_frame>
    <description>Maternal TXA-related side-effects (nausea, vomiting, dizziness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open label use of TXA or other antifibrinolytic</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>Use of any amount of open-label TXA (not blinded study drug) or other antifibrinolytic (eg., Amicar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Until hospital discharge, an average of 3 days</time_frame>
    <description>Mother's length of stay from delivery to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital re-admission</measure>
    <time_frame>within 6 weeks postpartum</time_frame>
    <description>Re-admission to the hospital after initial postpartum discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any transfusion-associated reactions</measure>
    <time_frame>within 7 days postpartum</time_frame>
    <description>One more transfusion-associated reactions, such as fever, urticaria, anaphylaxis, alloimmunization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">11000</enrollment>
  <condition>Obstetrical Complications</condition>
  <condition>Hemorrhage</condition>
  <condition>Labor and Delivery</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid for intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline for intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled or unscheduled cesarean delivery

          2. Singleton or twin gestation

        Exclusion Criteria:

          1. Age less than 18 years

          2. Transfusion or planned transfusion of any blood products during the current admission
             because the primary outcome is already pre-determined and the need for transfusion
             will be unrelated to perioperative hemorrhage

          3. Recent diagnosis or history of venous thromboembolism or arterial thrombosis because
             TXA is a risk factor for thromboembolism, and its use is contraindicated

          4. Known congenital or acquired thrombophilias, including antiphospholipid antibody
             syndrome, because of the increased risk of thrombosis

          5. Seizure disorder (including eclampsia) because TXA is a GABA receptor antagonist, and
             its use has been associated with postoperative seizures

          6. Serum creatinine 1.2 or higher or on dialysis, with renal disease, or a history of
             renal insufficiency, because TXA is substantially excreted by the kidney, and impaired
             renal function may increase the risk of toxic reactions.

          7. Sickle cell disease, because of substantial use of perioperative transfusion unrelated
             to hemorrhage. Sickle cell trait is not an exclusion per se.

          8. Autoimmune diseases such as lupus, rheumatoid arthritis, Sjogren's disease, and
             inflammatory bowel disease because of hypercoagulability and the increased risk of
             thrombosis or thromboembolism

          9. Need for therapeutic dose of anticoagulation before delivery, because the risk of
             thrombosis may be increased with TXA

         10. Treatment with clotting factor concentrates, because the risk of thrombosis may be
             increased with TXA

         11. Presence of frank hematuria, because the risk of ureteral obstruction in those with
             upper urinary tract bleeding may be increased with TXA

         12. Patient refusal of blood products because the primary outcome is then pre-determined

         13. Pre-operative receipt of TXA

         14. Active cancer, because of risk of thromboembolism

         15. Congestive heart failure requiring treatment, because of risk of thrombosis

         16. History of retinal disease, because the risk of central retinal artery or vein
             obstruction may be increased with TXA

         17. Acquired defective color vision or subarachnoid hemorrhage, since TXA is
             contraindicated

         18. Hypersensitivity to TXA or any of the ingredients

         19. No hemoglobin and hematocrit result available from the last 4 weeks, since it is
             necessary to measure the post-operative change in hemoglobin and hematocrit

         20. Scheduled cesarean delivery and quota for scheduled deliveries already met. Quotas on
             the number of scheduled and unscheduled deliveries will be placed to ensure
             approximately equal distribution of scheduled and unscheduled cesarean deliveries.

         21. Participation in this trial in a previous pregnancy. Patients who were screened in a
             previous pregnancy, but not randomized, may be included.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Thom, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uma Reddy, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>NICHD Project Scientist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uma Reddy, M.D.</last_name>
    <phone>301-496-1074</phone>
    <email>reddyu@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Thom, Ph.D.</last_name>
    <phone>(301) 881-9260</phone>
    <email>e_thom@bsc.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Harris, BSN</last_name>
      <phone>205-996-6262</phone>
      <email>stacylharris@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan TN Tita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University-Prentice Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Mallett, RN BSN CCRC</last_name>
      <phone>312-503-3200</phone>
      <email>g-mallett@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>William Grobman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bousleiman</last_name>
      <phone>212-305-4348</phone>
      <email>sb1080@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Gyamfi-Bannerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Clark, RN</last_name>
      <phone>919-350-6117</phone>
      <email>kelly_clark@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Thorp, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve-MetroHealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Dalton, RN</last_name>
      <phone>216-778-7533</phone>
      <email>wdalton@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Edward Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Bartholomew, RN, BSN</last_name>
      <phone>614-685-3229</phone>
      <email>anna.bartholomew@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Catalin S Buhimschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Craig, BSN</last_name>
      <phone>212-662-3926</phone>
      <email>jennifer.craig@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Parry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Bickus, BS, RN</last_name>
      <phone>412-641-4072</phone>
      <email>mbickus@mail.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Hyagriv Simhan, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Allard, RNC</last_name>
      <phone>401-274-1122</phone>
      <email>dallard@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Dwight J Rouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar, MSN</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>George R Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felecia Ortiz, RN BSN</last_name>
      <phone>713-500-6467</phone>
      <email>Felecia.Ortiz@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Suneet Chauhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hill, RN</last_name>
      <phone>801-585-7645</phone>
      <email>Kim.Hill@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W Varner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>HÃ¶gberg U. The World Health Report 2005: &quot;make every mother and child count&quot; - including Africans. Scand J Public Health. 2005;33(6):409-11.</citation>
    <PMID>16332605</PMID>
  </reference>
  <reference>
    <citation>Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Rep. 2010 May;58(19):1-19.</citation>
    <PMID>25075874</PMID>
  </reference>
  <reference>
    <citation>Kwee A, Bots ML, Visser GH, Bruinse HW. Emergency peripartum hysterectomy: A prospective study in The Netherlands. Eur J Obstet Gynecol Reprod Biol. 2006 Feb 1;124(2):187-92. Epub 2005 Jul 18.</citation>
    <PMID>16026917</PMID>
  </reference>
  <reference>
    <citation>Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. Births: Final Data for 2015. Natl Vital Stat Rep. 2017 Jan;66(1):1.</citation>
    <PMID>28135188</PMID>
  </reference>
  <reference>
    <citation>Magann EF, Evans S, Hutchinson M, Collins R, Howard BC, Morrison JC. Postpartum hemorrhage after vaginal birth: an analysis of risk factors. South Med J. 2005 Apr;98(4):419-22.</citation>
    <PMID>15898516</PMID>
  </reference>
  <reference>
    <citation>Ickx BE. Fluid and blood transfusion management in obstetrics. Eur J Anaesthesiol. 2010 Dec;27(12):1031-5. doi: 10.1097/EJA.0b013e32833c30e3. Review.</citation>
    <PMID>20613540</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007 Dec;13(6):680-5. Review.</citation>
    <PMID>17975390</PMID>
  </reference>
  <reference>
    <citation>Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci. 1968 Jun 28;146(2):642-58.</citation>
    <PMID>5254275</PMID>
  </reference>
  <reference>
    <citation>CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, MejÃ­a-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.</citation>
    <PMID>20554319</PMID>
  </reference>
  <reference>
    <citation>Oremus K, Sostaric S, Trkulja V, Haspl M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial. Transfusion. 2014 Jan;54(1):31-41. doi: 10.1111/trf.12224. Epub 2013 Apr 25.</citation>
    <PMID>23614539</PMID>
  </reference>
  <reference>
    <citation>Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety. J Cardiothorac Vasc Anesth. 2013 Dec;27(6):1201-7. doi: 10.1053/j.jvca.2013.04.003. Epub 2013 Sep 17.</citation>
    <PMID>24050855</PMID>
  </reference>
  <reference>
    <citation>As AK, Hagen P, Webb JB. Tranexamic acid in the management of postpartum haemorrhage. Br J Obstet Gynaecol. 1996 Dec;103(12):1250-1.</citation>
    <PMID>8968245</PMID>
  </reference>
  <reference>
    <citation>Wang HY, Hong SK, Duan Y, Yin HM. Tranexamic acid and blood loss during and after cesarean section: a meta-analysis. J Perinatol. 2015 Oct;35(10):818-25. doi: 10.1038/jp.2015.93. Epub 2015 Jul 30. Review.</citation>
    <PMID>26226243</PMID>
  </reference>
  <reference>
    <citation>Ray I, Bhattacharya R, Chakraborty S, Bagchi C, Mukhopadhyay S. Role of Intravenous Tranexamic Acid on Caesarean Blood Loss: A Prospective Randomised Study. J Obstet Gynaecol India. 2016 Oct;66(Suppl 1):347-52. doi: 10.1007/s13224-016-0915-x. Epub 2016 Jun 25.</citation>
    <PMID>27651628</PMID>
  </reference>
  <reference>
    <citation>Lakshmi SD, Abraham R. Role of Prophylactic Tranexamic Acid in Reducing Blood Loss during Elective Caesarean Section: A Randomized Controlled Study. J Clin Diagn Res. 2016 Dec;10(12):QC17-QC21. doi: 10.7860/JCDR/2016/21702.9050. Epub 2016 Dec 1.</citation>
    <PMID>28208943</PMID>
  </reference>
  <reference>
    <citation>Li C, Gong Y, Dong L, Xie B, Dai Z. Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention?: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jan;96(1):e5653. doi: 10.1097/MD.0000000000005653. Review.</citation>
    <PMID>28072700</PMID>
  </reference>
  <reference>
    <citation>Heesen M, BÃ¶hmer J, KlÃ¶hr S, Rossaint R, van de Velde M, Dudenhausen JW, Straube S. Prophylactic tranexamic acid in parturients at low risk for post-partum haemorrhage: systematic review and meta-analysis. Acta Anaesthesiol Scand. 2014 Oct;58(9):1075-85. doi: 10.1111/aas.12341. Epub 2014 Jul 29. Review.</citation>
    <PMID>25069636</PMID>
  </reference>
  <reference>
    <citation>Shahid A, Khan A. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg Pak. 2013 Jul;23(7):459-62. doi: 07.2013/JCPSP.459462.</citation>
    <PMID>23823946</PMID>
  </reference>
  <reference>
    <citation>Ker K, Shakur H, Roberts I. Does tranexamic acid prevent postpartum haemorrhage? A systematic review of randomised controlled trials. BJOG. 2016 Oct;123(11):1745-52. doi: 10.1111/1471-0528.14267. Epub 2016 Aug 24. Review.</citation>
    <PMID>27558956</PMID>
  </reference>
  <reference>
    <citation>Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, Goffinet F, Deneux-Tharaux C. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth. 2015 Apr;114(4):576-87. doi: 10.1093/bja/aeu448. Epub 2015 Jan 8. Review.</citation>
    <PMID>25571934</PMID>
  </reference>
  <reference>
    <citation>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26.</citation>
    <PMID>28456509</PMID>
  </reference>
  <reference>
    <citation>Simonazzi G, Bisulli M, Saccone G, Moro E, Marshall A, Berghella V. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2016 Jan;95(1):28-37. doi: 10.1111/aogs.12798. Epub 2015 Nov 12. Review.</citation>
    <PMID>26698831</PMID>
  </reference>
  <reference>
    <citation>Wei Z, Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med. 2015 Jun;25(3):151-62. doi: 10.1111/tme.12212. Epub 2015 May 29. Review.</citation>
    <PMID>26033447</PMID>
  </reference>
  <reference>
    <citation>Goswami U, Sarangi S, Gupta S, Babbar S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth. 2013 Oct;7(4):427-31. doi: 10.4103/1658-354X.121077.</citation>
    <PMID>24348295</PMID>
  </reference>
  <reference>
    <citation>Ahmadzia HK, Lockhart EL, Thomas SM, Welsby IJ, Hoffman MR, James AH, Murtha AP, Swamy GK, Grotegut CA. Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? J Neonatal Perinatal Med. 2017;10(1):1-7. doi: 10.3233/NPM-16139.</citation>
    <PMID>28304315</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, BussiÃ¨res JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017 Jan 12;376(2):136-148. doi: 10.1056/NEJMoa1606424. Epub 2016 Oct 23. Erratum in: N Engl J Med. 2018 Feb 22;378(8):782.</citation>
    <PMID>27774838</PMID>
  </reference>
  <reference>
    <citation>Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008 Apr;6(4):632-7. doi: 10.1111/j.1538-7836.2008.02921.x. Epub 2008 Jan 31.</citation>
    <PMID>18248600</PMID>
  </reference>
  <reference>
    <citation>Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005 Nov 15;143(10):697-706.</citation>
    <PMID>16287790</PMID>
  </reference>
  <reference>
    <citation>Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65-72.</citation>
    <PMID>7308275</PMID>
  </reference>
  <reference>
    <citation>Gilad O, Merlob P, Stahl B, Klinger G. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med. 2014 Oct;9(8):407-10. doi: 10.1089/bfm.2014.0027. Epub 2014 Jul 15.</citation>
    <PMID>25025926</PMID>
  </reference>
  <reference>
    <citation>Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014 Apr 3;370(14):1307-15. doi: 10.1056/NEJMoa1311485. Epub 2014 Feb 13.</citation>
    <PMID>24524551</PMID>
  </reference>
  <reference>
    <citation>Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015 Jun 16;(6):CD007872. doi: 10.1002/14651858.CD007872.pub3. Review.</citation>
    <PMID>26079202</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Cesarean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Obstetric Labor Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

